A study recently published in the November 2025 issue of journal Frontiers in Medicine suggests that intradermal injections of Botulinum Toxin A (BoNT-A), commonly known as Botox, may be a promising new treatment for persistent post-acne redness (erythema) and excessive skin oiliness (sebum production).
The study, which involved 30 adults, compared a single BoNT-A session on one cheek to three sessions of broadband light (BBL) therapy on the other over a three-month period. Key findings include:
- Superior Results: The BoNT-A treated side showed significantly greater and faster reductions in redness and sebum secretion compared to the BBL-treated side, with improvements persisting over the three months.
- Proposed Mechanism: Researchers believe BoNT-A helps by reducing sebum production (by inhibiting acetylcholine release at nerve endings that regulate oil glands) and by calming inflammation and vascular reactivity, which contributes to redness.
- Limitations: While promising, the article cautions that BoNT-A is not a definitive treatment for true pigment or dark spots (melanin) and does not kill acne bacteria. The study was small (30 participants) and short-term, so larger, longer trials are needed.
In conclusion, BoNT-A offers a convenient, single-session option for people with oily, acne-prone skin and persistent redness, but it should be considered an adjunct treatment alongside traditional post-acne care.
Why does this matter to you?
CC Exclusive Analysis:
Acne is a multigenerational aesthetic issue that, although treatable, is not preventable. It’s important to understand the multiple tools available to you for treating this, for some, life-altering issue in order to provide positive results for your patients in various stages of life. The treatment of this condition can change patients’ lives and help become the foundation of a lifelong patient and advocate for your services.
Leave a Reply